41 related articles for article (PubMed ID: 24115268)
1. Spatial MS multiomics on clinical prostate cancer tissues.
Truong JXM; Rao SR; Ryan FJ; Lynn DJ; Snel MF; Butler LM; Trim PJ
Anal Bioanal Chem; 2024 Mar; 416(7):1745-1757. PubMed ID: 38324070
[TBL] [Abstract][Full Text] [Related]
2. Precise diagnosis and risk stratification of prostate cancer by comprehensive serum metabolic fingerprints: a prediction model study.
Fei X; Du X; Wang J; Liu J; Gong Y; Zhao Z; Cao Z; Fu Q; Zhu Y; Dong L; Dong B; Pan J; Sun W; Xie S; Xue W
Int J Surg; 2024 Mar; 110(3):1450-1462. PubMed ID: 38181121
[TBL] [Abstract][Full Text] [Related]
3. Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.
Larkin SE; Johnston HE; Jackson TR; Jamieson DG; Roumeliotis TI; Mockridge CI; Michael A; Manousopoulou A; Papachristou EK; Brown MD; Clarke NW; Pandha H; Aukim-Hastie CL; Cragg MS; Garbis SD; Townsend PA
Br J Cancer; 2016 Oct; 115(9):1078-1086. PubMed ID: 27685442
[TBL] [Abstract][Full Text] [Related]
4. Link test--A statistical method for finding prostate cancer biomarkers.
Deng X; Geng H; Bastola DR; Ali HH
Comput Biol Chem; 2006 Dec; 30(6):425-33. PubMed ID: 17126079
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer classification based on mass spectrometry analysis of sera.
Wu B; Abbott T; Fishman D; McMurray W; Mor G; Stone K; Ward D; Williams K; Zhao H
Cancer Inform; 2007 Feb; 2():123-32. PubMed ID: 19458764
[TBL] [Abstract][Full Text] [Related]
6. Cell-Free DNA, MicroRNAs, Proteins, and Peptides as Liquid Biopsy Biomarkers in Prostate Cancer and Bladder Cancer.
Chen H; Xu C; Fang Z; Mao S
Methods Mol Biol; 2023; 2695():165-179. PubMed ID: 37450118
[TBL] [Abstract][Full Text] [Related]
7. MALDI-TOF/MS Analysis of Non-Invasive Human Urine and Saliva Samples for the Identification of New Cancer Biomarkers.
Zambonin C; Aresta A
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335287
[TBL] [Abstract][Full Text] [Related]
8. Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery.
Lee B; Mahmud I; Marchica J; Dereziński P; Qi F; Wang F; Joshi P; Valerio F; Rivera I; Patel V; Pavlovich CP; Garrett TJ; Schroth GP; Sun Y; Perera RJ
Sci Rep; 2020 Feb; 10(1):3716. PubMed ID: 32111915
[TBL] [Abstract][Full Text] [Related]
9. A New Era of Prostate Cancer Precision Medicine.
Malik A; Srinivasan S; Batra J
Front Oncol; 2019; 9():1263. PubMed ID: 31850193
[TBL] [Abstract][Full Text] [Related]
10. Approaches to urinary detection of prostate cancer.
Eskra JN; Rabizadeh D; Pavlovich CP; Catalona WJ; Luo J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):362-381. PubMed ID: 30655600
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
[TBL] [Abstract][Full Text] [Related]
12. Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine.
Wang Z; Liu X; Ho RL; Lam CW; Chow MS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399658
[TBL] [Abstract][Full Text] [Related]
13. Proteomics and peptidomics: moving toward precision medicine in urological malignancies.
Di Meo A; Pasic MD; Yousef GM
Oncotarget; 2016 Aug; 7(32):52460-52474. PubMed ID: 27119500
[TBL] [Abstract][Full Text] [Related]
14. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
Flatley B; Wilmott KG; Malone P; Cramer R
Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
[TBL] [Abstract][Full Text] [Related]
15. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.
Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Iwabuchi I; Yoneyama T; Hashimoto Y; Koie T; Kamimura N; Mori K; Yamaya K; Ohyama C
Oncol Rep; 2009 Jan; 21(1):73-9. PubMed ID: 19082445
[TBL] [Abstract][Full Text] [Related]
16. Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles.
Calvano CD; Aresta A; Iacovone M; De Benedetto GE; Zambonin CG; Battaglia M; Ditonno P; Rutigliano M; Bettocchi C
J Pharm Biomed Anal; 2010 Mar; 51(4):907-14. PubMed ID: 19939598
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer biomarker discovery using high performance mass spectral serum profiling.
Oh JH; Lotan Y; Gurnani P; Rosenblatt KP; Gao J
Comput Methods Programs Biomed; 2009 Oct; 96(1):33-41. PubMed ID: 19423179
[TBL] [Abstract][Full Text] [Related]
18. Protein profiling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and infrared imaging: a review.
Bakry R; Rainer M; Huck CW; Bonn GK
Anal Chim Acta; 2011 Mar; 690(1):26-34. PubMed ID: 21414433
[TBL] [Abstract][Full Text] [Related]
19. MALDI mass spectrometry in prostate cancer biomarker discovery.
Flatley B; Malone P; Cramer R
Biochim Biophys Acta; 2014 May; 1844(5):940-9. PubMed ID: 23831156
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
